Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 33c
November 7, 2017 4:30 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $3.22, $0.33 better than the analyst estimate of $2.89. Revenue for the quarter came in at $412 million versus the consensus estimate of $421 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2017 EPS of $10.70-$11.20, versus the consensus of $10.90.... More
